Sorting out release, uptake and processing of alpha‐synuclein during prion‐like spread of pathology
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Parkinson's disease is a progressive neurological disorder that is characterized by the formation of intracellular protein inclusion bodies composed primarily of a misfolded and aggregated form of the protein α‐synuclein. There is growing evidence that supports the prion‐like hypothesis of α‐synuclein progression. This hypothesis postulates that α‐synuclein is a prion‐like pathological agent and is responsible for the progression of Parkinson pathology in the brain. Potential misfolding or aggregation of α‐synuclein that might occur in the peripheral nervous system as a result of some insult, environmental or genetic (or more likely a combination of both) that might spread into the midbrain, eventually causing degeneration of the neurons in the substantia nigra. As the disease progresses further, it is likely that α‐synuclein pathology continues to spread throughout the brain, including the cortex, leading to deterioration of cognition and higher brain functions. While it is unknown why α‐synuclein initially misfolds and aggregates, a great deal has been learned about how the cell handles aberrant α‐synuclein assemblies. In this review, we focus on these mechanisms and discuss them in an attempt to define the role that they might play in the propagation of misfolded α‐synuclein from cell‐to‐cell. image The prion‐like hypothesis of α‐synuclein pathology suggests a method for the transmission of misfolded α‐synuclein from one neuron to another. This hypothesis postulates that misfolded α‐synuclein becomes aggregation prone and when released and taken up by neighboring cells, seeds further misfolding and aggregation. In this review we examine the cellular mechanisms that are involved in the processing of α‐synuclein and how these may contribute to the prion‐like propagation of α‐synuclein pathology. This article is part of a special issue on Parkinson disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 3×
“They revealed that a-syn-positive LB and LN are most abundant in olfactory structures and the dorsal motor nucleus of the vagal nerve in early disease, and that they then appear in interconnected brain regions as the disease progresses (Braak et al. 2004).”
BackgroundLuk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · cited 2×
“Two distinct, but complementary systems; the Autophagy/Lysosomal Pathway (ALP) and the ubiquitin proteasome system (UPS) generally handle this process and monomeric a-syn can be degraded by both systems (Cuervo et al. 2004; Dargemont and Ossareh-Nazari 2012).”
BackgroundLi, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Self-citationLewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
Braak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H. A., Kittel, A., & Saitoh, T. (1995) · Neuron · doi:10.1016/0896-6273(95)90302-x · Cited by 1,316 · cited 1×
“This 140 amino acid protein is enriched in pre-synaptic nerve terminals (Iwai et al. 1995), yet, it is also found within the nucleus (Mori et al. 2002).”
Backgroundα-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
Bartels, T., Choi, J. G., & Selkoe, D. J. (2011) · Nature · doi:10.1038/nature10324 · Cited by 1,263 · cited 1×
“Multimeric forms of a-syn, principally tetrameric, have been isolated from neuronal and non-neuronal cell lines, brain tissue, and living human cells (Bartels et al. 2011; Wang et al. 2011; Burr e et al. 2014).”
Backgroundα-Synuclein strains cause distinct synucleinopathies after local and systemic administration
Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., & Baekelandt, V. (2015) · Nature · doi:10.1038/nature14547 · Cited by 1,130 · cited 1×
“Indeed, injections of ‘fibrils’ and ‘ribbons’ (two distinct forms of a-syn aggregates) do lead to distinct histopathological and behavioral phenotypes when injected into the brains of rats (Peelaerts et al. 2015).”
BackgroundShimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., & Selkoe, D. J. (2001) · Science · doi:10.1126/science.1060627 · Cited by 1,053
Cited by
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationPathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Mao, X., Ou, M. T., Karuppagounder, S. S., Kam, T.-I., Yin, X., Xiong, Y., Ge, P., Umanah, G. E., Brahmachari, S., Shin, J.-H., et al. (2016) · Science · doi:10.1126/science.aah3374 · Cited by 690
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis
Johnson, M. E., Stecher, B., Labrie, V., Brundin, L., & Brundin, P. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.09.007 · Cited by 310
Self-citationPropagation of Protein Aggregation in Neurodegenerative Diseases
Vaquer-Alicea, J., & Diamond, M. I. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045049 · Cited by 310
Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease
George, S., Rey, N. L., Tyson, T., Esquibel, C., Meyerdirk, L., Schulz, E., Pierce, S., Burmeister, A. R., Madaj, Z., Steiner, J. A., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0335-3 · Cited by 229
Self-citationDNA methylation in Parkinson's disease
Wüllner, U., Kaut, O., deBoni, L., Piston, D., & Schmitt, I. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13646 · Cited by 107
Berrío Sánchez, J., Cucarian Hurtado, J., Barcos Nunes, R., & de Oliveira, A. A. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0011 · Cited by 7
Metadata
- Authors
- Tyson, T., Steiner, J. A., & Brundin, P.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-02-10
- Volume
- 139
- Issue
- S1
- Pages
- 275-289
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2187596915
- Cited by
- 102
- References
- 44
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.